Tae-Jin Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8396879/publications.pdf

Version: 2024-02-01

840776 752698 31 460 11 20 h-index citations g-index papers 36 36 36 790 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version. Applied Health Economics and Health Policy, 2022, 20, 467-477.	2.1	7
2	Cost-effectiveness of using amyloid positron emission tomography in individuals with mild cognitive impairment. Cost Effectiveness and Resource Allocation, 2021, 19, 50.	1.5	9
3	How can we improve patients' access to new drugs under uncertainties? : South Korea's experience with risk sharing arrangements. BMC Health Services Research, 2021, 21, 967.	2.2	6
4	Patent challenges and factors associated with successful patent challengers under the patent linkage system: recent evidence from South Korea after the Korea United States free trade agreement. Globalization and Health, 2021, 17, 116.	4.9	2
5	Disease severity classification and COVID-19 outcomes, Republic of Korea. Bulletin of the World Health Organization, 2021, 99, 62-66.	3.3	50
6	Equity of health care financing in South Korea: 1990–2016. BMC Health Services Research, 2021, 21, 1327.	2.2	2
7	Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate. Frontiers in Pharmacology, 2020, 11, 232.	3.5	3
8	Cost Sharing and Financial Protection in South Korea. World Scientific Series in Global Healthcare Economics and Public Policy, 2020, , 65-74.	0.1	O
9	The Aassociation Between the Basic Old-Age Pension and Depression of the Older Adults in Korea. Journal of Preventive Medicine and Public Health, 2020, 53, 332-341.	1.9	2
10	Understanding of for whom, under what conditions and how the compulsory licensing of pharmaceuticals works in Brazil and Thailand: A realist synthesis. Global Public Health, 2019, 14, 122-134.	2.0	6
11	Does the Patent Linkage System Prolong Effective Market Exclusivity? Recent Evidence From the Korea-U.S. Free Trade Agreement in Korea. International Journal of Health Services, 2019, 49, 306-321.	2.5	7
12	Compulsory licensing of pharmaceuticals reconsidered: Current situation and implications for access to medicines. Global Public Health, 2018, 13, 1430-1440.	2.0	22
13	The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries. Global Public Health, 2018, 13, 1169-1178.	2.0	15
14	Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States. Globalization and Health, 2018, 14, 101.	4.9	18
15	Relationship among family environment, self-control, friendship quality, and adolescents' smartphone addiction in South Korea: Findings from nationwide data. PLoS ONE, 2018, 13, e0190896.	2.5	107
16	Evaluation of a technology-enhanced integrated care model for frail older persons: protocol of the SPEC study, a stepped-wedge cluster randomized trial in nursing homes. BMC Geriatrics, 2017, 17, 88.	2.7	16
17	Identification of Downstream Genes of the mTOR Pathway that Predict Recurrence and Progression in Non-Muscle Invasive High-Grade Urothelial Carcinoma of the Bladder. Journal of Korean Medical Science, 2017, 32, 1327.	2.5	5
18	Has the Copayment Ceiling Improved Financial Protection in the Korean National Health Insurance System? Evidence From the 2009 Policy Change. Journal of Preventive Medicine and Public Health, 2017, 50, 393-400.	1.9	4

TAE-JIN LEE

#	Article	IF	CITATIONS
19	Treatment strategies for stage IB cervical cancer: A cost-effectiveness analysis from Korean, Canadian and US perspectives. Gynecologic Oncology, 2016, 140, 83-89.	1.4	8
20	Cost-Effectiveness of Nationwide Opportunistic Screening Program for Dementia in South Korea. Journal of Alzheimer's Disease, 2015, 44, 195-204.	2.6	16
21	P70S6K and Elf4E Dual Inhibition Is Essential to Control Bladder Tumor Growth and Progression in Orthotopic Mouse Non-muscle Invasive Bladder Tumor Model. Journal of Korean Medical Science, 2015, 30, 308.	2.5	6
22	Factors Determining Children's Private Health Insurance Enrolment and Healthcare Utilization Patterns: Evidence From the 2008 to 2011 Health Panel Data. Journal of Preventive Medicine and Public Health, 2015, 48, 319-329.	1.9	4
23	Establishment of an Orthotopic Mouse Non-Muscle Invasive Bladder Cancer Model Expressing the Mammalian Target of Rapamycin Signaling Pathway. Journal of Korean Medical Science, 2014, 29, 343.	2.5	3
24	Cost-of-Illness and Quality of Life in Patients with Ankylosing Spondylitis at a Tertiary Hospital in Korea. Journal of Korean Medical Science, 2014, 29, 190.	2.5	18
25	The cost-effectiveness of selective lymphadenectomy based on a preoperative prediction model in patients with endometrial cancer: Insights from the US and Korean healthcare systems. Gynecologic Oncology, 2014, 135, 518-524.	1.4	11
26	Prevalence and healthcare utilization of herpes zoster and postherpetic neuralgia in Korea: Disparity among patients with different immune status. Epidemiology and Health, 2014, 36, e2014012.	1.9	16
27	The Factors Contributing to Expenditures on Over-the-Counter Drugs in South Korea. Value in Health Regional Issues, 2013, 2, 147-151.	1.2	12
28	Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea. Value in Health Regional Issues, 2012, 1, 59-65.	1.2	7
29	Cost of Illness and Quality of Life of Patients with Rheumatoid Arthritis in South Korea. Value in Health, 2012, 15, S43-S49.	0.3	19
30	The Incidence of Thyroid Cancer Is Affected by the Characteristics of a Healthcare System. Journal of Korean Medical Science, 2012, 27, 1491.	2.5	48
31	Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context. Journal of Breast Cancer, 2010, 13, 286.	1.9	5